OCBC stock slips on JPMorgan downgrade as Feb. 25 results loom
11 January 2026
1 min read

OCBC stock slips on JPMorgan downgrade as Feb. 25 results loom

Singapore, Jan 11, 2026, 15:04 SGT — Market closed

Oversea-Chinese Banking Corporation (OCBC) shares fell 1.8% on Friday to close at S$19.80 after JPMorgan cut its rating on the lender to “neutral” from “overweight”, while lifting its target price to S$20.50. DBS and United Overseas Bank ended higher on the day. 1

The call matters because OCBC goes into full-year results season trading near recent peaks, with little room left for soft guidance. The bank is scheduled to announce its 2025 full-year results on Feb. 25, a key read for dividends and buybacks and for how quickly earnings cool as rate tailwinds fade. 2

Friday’s slide left the stock on the day’s low, after it had traded close to its 52-week high of S$20.25 earlier this year. OCBC’s 52-week range runs from S$14.35 to S$20.25, and about 8.42 million shares changed hands on Friday. 3

The wider Singapore market held firm. The Straits Times Index ended up 0.1% on Friday, with investors also looking to a possible U.S. Supreme Court ruling on tariffs; “Tariffs are not going anywhere,” Neil Wilson, a UK investment strategist at Saxo Markets, said. 4

JPMorgan’s new target implies roughly 3.5% upside from Friday’s close, though the downgrade flags tighter risk-reward after the rally. A price target is an analyst estimate of where a stock could trade over the next 12 months, not a guarantee.

With markets shut over the weekend, traders will look for follow-through selling when Singapore reopens on Monday, or for dip-buyers to show up quickly around S$19.80. A quick rebound would point to demand for bank yield; another leg down would suggest the downgrade hit a nerve.

OCBC has already warned that margins are coming under pressure. Net interest margin — the spread between what a bank earns on loans and pays on deposits — slipped to 1.84% from 2.18% a year earlier, and the bank forecast net interest income would fall by a mid-to-high single-digit percentage in 2025; then-CEO Helen Wong said it was its “strongest quarter this year” even “despite a declining interest-rate environment.” 5

But there is an obvious risk case: faster rate cuts or tougher deposit competition could squeeze margins more than expected, while a pickup in credit costs would hit earnings just as the stock is priced near its highs. Fee income tied to wealth management could also prove more uneven than investors have been betting on.

Next up is Feb. 25, when OCBC reports full-year results and lays out how it sees margins, credit and capital returns in 2026. Until then, the stock’s tape is likely to keep circling two levels: S$20.25 on the top side, and Friday’s S$19.80 close underneath.

Stock Market Today

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

Home Depot stock price: jobs, inflation and a Feb. 24 earnings test loom

7 February 2026
Home Depot shares rose 0.7% to $385.15 Friday, trading between $379.10 and $386.37. Investors await a delayed U.S. jobs report Wednesday and CPI data Friday, both postponed by a brief government shutdown. Home Depot reports fourth-quarter earnings Feb. 24. The Dow closed above 50,000 for the first time.
JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

JPMorgan stock price jumps 4% into weekend as Wall Street braces for a busy data week

7 February 2026
JPMorgan shares rose 3.95% to $322.40 Friday, outpacing other major banks as U.S. stocks rallied and the Dow closed above 50,000 for the first time. The bank recently completed a $3 billion subordinated notes offering. Investors are watching for delayed U.S. jobs data and inflation figures next week, ahead of JPMorgan’s Feb. 23 company update.
AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

AbbVie stock price: ABBV ends week near $223 after earnings swing — what to watch next

7 February 2026
AbbVie shares rose 2% to $223.43 Friday, capping a volatile week marked by earnings and drug sales scrutiny. Moody’s upgraded AbbVie’s credit rating to A2, citing strong performance in immunology and neuroscience. Investors remain focused on Skyrizi and Rinvoq growth amid rising competition and recent regulatory filings. Trading volume stayed below average, with the stock still 9% off its 52-week high.
SK hynix stock price slips into Monday after S&P upgrade, tech selloff

SK hynix stock price slips into Monday after S&P upgrade, tech selloff

7 February 2026
SK hynix shares closed at 839,000 won, down 0.36% Friday and 8% for the week, as tech stocks retreated across Asia. S&P Global Ratings upgraded the chipmaker to “BBB+” with a positive outlook, citing strong HBM sales. The KOSPI fell 1.4% Friday, ending a six-week winning streak. Traders await Monday’s Seoul open for signs of further tech weakness.
CapitaLand Investment stock rises to S$2.89 as logistics push sharpens focus on Feb 11 results
Previous Story

CapitaLand Investment stock rises to S$2.89 as logistics push sharpens focus on Feb 11 results

UOB stock in focus after fresh buyback filing as rate bets return to the fore
Next Story

UOB stock in focus after fresh buyback filing as rate bets return to the fore

Go toTop